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Rickettsialpox in
Turkey
To the Editor: Rickettsialpox is
often described as a chickenpox-like
disease and is caused by Rickettsia
akari, a spotted fever group Rickettsia
that is transmitted to humans by the
bite of mites (Liponyssoides
sanguineus). Although the mite host
(typically a mouse) is widely
distributed in cities, the disease is
infrequently diagnosed. It is typically
characterized in patients by the
appearance of a primary eschar at the
site of a mite bite followed by fever,
headache, and development of a
papulovesicular rash. Symptoms
normally appear 9–14 days after the
mite bite and are often unnoticed by
the affected person. In documented
rickettsialpox cases, the presence of a
papule that ulcerates and becomes a
scar approximately 0.5–3.0 cm in
diameter is reported (1–3). Three to 7
days later, symptoms are more
pronounced, with patients
experiencing the sudden onset of
chills, fever, and headache followed
by myalgia and the appearence of
generalized vesicular skin rashes.
Less frequently, photophobia,
conjunctival injection, cough,
generalized lymphadenopathy, and
vomiting are reported.
The first well-described clinical
case of rickettsialpox was docu-
mented in New York City in 1946 (1).
Historically, most documented
rickettsialpox cases have occurred in
large metropolitan areas of the United
States (2), where the causative agent,
R. akari, circulates primarily between
the house mouse (Mus musculus) and
its mite (Liponyssoides sanguineus).
Recently, rickettsialpox cases have
been reported from Croatia, Ukraine,
South Africa, Korea, and North
Carolina (3,4). R. akari was isolated
from the blood of a patient suspected
of having Mediterranean spotted fever
rather than rickettsialpox; this was the
first human isolate of R. akari
reported in >40 years (4). Recent
reports of a rickettsialpox case in
North Carolina (3), R. akari
seropositivity found in HIV-positive
intravenous drug users in the inner
city of Baltimore, Maryland (5), and
in Central and East Harlem, New York
City (6), as well as rickettsialpox
cutaneous eruption in an HIV patient
in New York (7), indicate that R. akari
rickettsiosis is more common than
previously thought and presents the
risk of sporadic outbreaks worldwide.
We describe the clinical
presentation of rickettsialpox in a 9-
year-old boy from Nevpehir, located
in the middle region of Turkey.
Previously, a report from the Antalya
area of Turkey described the
prevalence of serum immunoglobulin
(Ig) G antibodies in humans directed
against  R. conorii (spotted fever
group  Rickettsia) (8); however,
rickettsialpox was not reported in
Turkey. This report of what we
believe to be the first described
rickettsialpox case from Turkey
further extends the recognized
geographic distribution of R. akari.
A 9-year-old boy was admitted to
the Kayseri hospital with fever >39°C
and generalized papulovesicular
exanthema. One week before
admission, fever, profuse sweating,
headache, and dysuria were present.
On admission, physical examination
indicated generalized vesicular,
bullouse, and papular exanthema
involving the lips and oral cavity.
Notable pathologic findings at
admission included a black eschar on
the boy’s penis, bilateral prominent
conjunctival ejection, and bilateral
lower pulmonary rales. The leukocyte
count was 13,300/mm3, hemoglobin
was 14.49 mg/dL, and the platelet
count was 544,000/mm3. Serum
electrolytes and blood urea nitrogen
levels and results of coagulation study
and urine analysis were normal.
Routine blood cultures taken 24 hours
postadmission were sterile. Specific
antibodies (IgG; IgM) against
Varicella were not detected in serum
samples (Duzen Laboratories,
Ankara, Turkey). Additionally, the
patient reported mice on the family’s
farm.
A diagnosis of rickettsialpox was
made and doxycycline treatment (200
mg/kg) was initiated. The patient
serum sample was tested by indirect
immunofluorescence assay (IFA) for
IgG and IgM antibodies reactive with
R. akari (Kaplan strain), R. typhi
(Wilmington),  R. rickettsii (Sheila
Smith), and R. conorii (Malish 7).
Serum IgG titers of 1/1280 and IgM
of 1/40 to R. akari were detected and
confirmed through cross-adsorption
with rickettsial antigens (R. rickettsii,LETTERS
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R. conorii) (9,10). Higher reciprocal
titers were obtained against R. akari
antigens than against R. rickettsii and
R. conorii antigens (reciprocol titers
of 1,024 vs. 512 and 512,
respectively). We observed a
difference in reduction in antibody
titers against R. akari after adsorption
with  R. akari (Kaplan) (<16), R.
rickettsii (256), and R. conorii (256).
Antibodies against R. typhi were not
detected. The IFAresult confirmed the
clinical diagnosis of R. akari
infection. After 2 days of doxycycline
treatment, the patient was afebrile,
and the rickettsialpox infection
resolved without scars or
complications.
In summary, we present a case in
which the presence of an eschar on the
patient’s penis, the failure of lesions
to appear in crops, the sparsity of
lesions, and mice on the family’s farm
led to a diagnosis of rickettsialpox,
which was confirmed by cross-
adsorption serologic findings. This
case indicates that rickettsialpox is an
emerging infectious disease in
Turkey. We recommend further
studies to define the prevalence of R.
akari and the worldwide distribution
of rickettsialpox.
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Human
Granulocytic
Ehrlichiosis in
Estonia
To the Editor: We report a case of
a 24-year-old woman living in a rural
area of Estonia who had weakness,
chills, and diarrhea on May 10, 2002.
On day 5 of the illness, she was
admitted to the Department of
Infectious Diseases, University of
Tartu, with high fever (38.5°C) and
muscle pains throughout her body.
Examination showed mild jaundice,
painful and enlarged liver, and inabil-
ity to move. Throat was erythematous,
and enlarged lymph nodes were pal-
pable on the neck.
Laboratory findings included the
following: leukopenia 2.04x109/L;
erythrocytes 4.08x1012/L; hemoglobin
130 g/L; thrombocytopenia 36x109/L;
eosinophils 0%; basophils 1.0%;
monocytes 7.5%; lymphocytes 38.0%;
neutrophils 51.0%; reactive lymph-
cytes 2.0%; plasma cells 0.5%; C-
reactive protein 38 mg/L (normal <5
mg/L); bilirubin 95 µmol/L (normal
<17  µmol/L); aspartate aminotrans-
ferase 121 U/L (normal <31 U/L); ala-
nine aminotransferase 108 UL(normal
<31 U/L); and alcaline phosphatase
200 U/L (normal 35–104 U/L).
Ehrlichiosis was suspected by clinical
symptoms and leukopenia, thrombo-
cytopenia, and elevated transaminas-
es. 
Human granulocytic ehrlichiosis
(HGE) is an emerging tick-borne dis-
ease described for the first time in
1994 in the United States (1). The first
European case of HGE was reported
in Slovenia in 1996 (2). Infection with
Ehrlichia phagocytophila, the agent
of HGE, occurs in areas endemic for
Borrelia burgdorferi (3). In Estonia,
Lyme borrreliosis is frequently diag-
nosed in humans but the occurrence of
ehrlichiosis has not been established
for this region, despite our having
found some seropositive results in
Lyme borrreliosis patients (4).
This case of ehrlichiosis is the first
diagnosed in Estonia. The initial diag-
nosis was based on a typical clinical
spectrum of symptoms and clinical
laboratory findings, which are rela-
tively nonspecific, making the diag-
nosis problematic (5). Polymerase
chain reaction results for Ehrlichia
were negative, and we did not find
morula in the blood smear. Indirect
immunofluorescence assay (IFA,
MRL Diagnostics, Cypress, CA) was
used as a confirmatory serologic test.
However, results of this assay are
often negative during the initial phase